MOR102
MOR102 is a fully human IgG4 monoclonal antibody and an ICAM-1 inhibitor, lacking cross-reactivity with ICAM-2 and ICAM-3. MOR102 binds to the LFA-1 binding site within ICAM-1 domain 1, blocks ICAM-1/LFA-1 interaction, binds human keratinocytes with increased binding to interferon-γ-stimulated keratinocytes. MOR102 inhibits lymphocyte adhesion, reduces lymphocyte proliferation, prevents local T-cell activation, reduces inflammatory infiltrate, restores orthokeratotic differentiation, and reduces epidermal thickness. MOR102 can be used for the research of psoriasis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Fab-G4-nd
Human
MOR102 (0.04-10 μg/mL; 30 min) potently inhibits adhesion of human SKW-3 T-cell leukaemia cells to immobilized recombinant ICAM-1 with an IC50 of 3 nM[1].
MOR102 (0.5-50 μg/mL; 4 days) reduces proliferation of human peripheral blood mononuclear cells in mixed lymphocyte cultures[1].
MOR102 (10 μg/mL; overnight) binds to human HaCaT keratinocytes, with increased binding observed on IFN-γ-stimulated HaCaT cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MOR102 (10 mg/kg; i.p.; every other day; 4 weeks) induces orthokeratotic differentiation, reduces epidermal thickness, and decreases inflammatory infiltrate in human chronic plaque-stage psoriasis skin grafts on SCID mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C.B17 SCID mice (6-8 weeks old) transplanted with human split skin grafts[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every alternate day; 4 weeks from day 22-50 after transplantation
-
Result:Reduced mean epidermal thickness to 255 μm, a significant reduction compared to control.
Reduced mean inflammatory infiltrate density to 136 cells per high-power field, a marked reduction compared to PBS-treated controls.
Induced reconstitution of orthokeratotic differentiation of the epidermis, with moderate acanthosis, mild papillomatosis, a web-like corneal layer with mild remaining parakeratosis, and a re-established granular layer.
Demonstrated intense staining of keratinocytes in grafts via immunohistochemistry, confirming targeting of ICAM-1 on keratinocytes.
-
Animal Model:SCID mice transplanted with human split skin grafts[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; every other day; 4 weeks
-
Result:Reconstituted orthokeratotic differentiation of the transplanted skin.
Significantly reduced epidermal thickness.
Markedly reduced the inflammatory infiltrate within the graft.
ICAM1/CD54
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Boehncke WH, et al. Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model. Br J Dermatol. 2005;153(4):758-766. [Content Brief]
[2]. Mrowietz U, et al. Leukocyte adhesion: a suitable target for anti-inflammatory drugs. Curr Pharm Des. 2006;12(22):2825-2831. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
MOR102 Related Classifications
HY-P992413 Related Classifications
Powered by Bioz